Cogent Biosciences (COGT) Revenue & Revenue Breakdown
Cogent Biosciences Revenue Highlights
Main Segment (Y)
Preclinical Research And Clinical Development
Main Geography (Y)
Preclinical Research And Clinical Development
Cogent Biosciences Revenue by Period
Cogent Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $7.87M | -65.02% |
| 2019-12-31 | $22.50M | 131.14% |
| 2018-12-31 | $9.73M | 16.44% |
| 2017-12-31 | $8.36M | 31.55% |
| 2016-12-31 | $6.36M | 112.83% |
| 2015-12-31 | $2.99M | - |
Cogent Biosciences generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Cogent Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $5.59M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2020-09-30 | $312.00K | -40.91% |
| 2020-06-30 | $528.00K | -92.49% |
| 2020-03-31 | $7.03M | -54.01% |
| 2019-12-31 | $15.29M | 1398.82% |
| 2019-09-30 | $1.02M | -67.50% |
| 2019-06-30 | $3.14M | 2.78% |
| 2019-03-31 | $3.05M | -19.76% |
| 2018-12-31 | $3.81M | 86.25% |
| 2018-09-30 | $2.04M | 22.63% |
| 2018-06-30 | $1.67M | -24.95% |
| 2018-03-31 | $2.22M | 4.57% |
| 2017-12-31 | $2.12M | -8.92% |
| 2017-09-30 | $2.33M | 12.12% |
| 2017-06-30 | $2.08M | 13.79% |
| 2017-03-31 | $1.83M | - |
Cogent Biosciences generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Cogent Biosciences Revenue Breakdown
Cogent Biosciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 19 | Dec 18 |
|---|---|---|
| Preclinical Research And Clinical Development | $25.00M | $25.00M |
Cogent Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 19: Preclinical Research And Clinical Development (100.00%).
Cogent Biosciences Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 19 | Dec 18 |
|---|---|---|
| Preclinical Research And Clinical Development | $25.00M | $25.00M |
Cogent Biosciences's latest annual revenue breakdown by geography, as of Dec 19: Preclinical Research And Clinical Development (100.00%).
Cogent Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals | $270.26M | $108.63M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| MRSN | Mersana Therapeutics | $36.85M | $2.29M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| FIXX | Q32 Bio | $1.16M | - |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| CGEM | Cullinan Oncology | - | - |
| COGT | Cogent Biosciences | - | - |
| VRNA | Verona Pharma | - | - |
| OLMA | Olema Pharmaceuticals | - | - |
| CERE | Cerevel Therapeutics | - | - |
| KURA | Kura Oncology | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| VTYX | Ventyx Biosciences | - | - |
| LRMR | Larimar Therapeutics | - | - |
| SANA | Sana Bio | - | - |
| ZNTL | Zentalis Pharmaceuticals | - | - |
| KALV | KalVista Pharmaceuticals | - | - |
COGT Revenue FAQ
What is Cogent Biosciences’s yearly revenue?
Cogent Biosciences's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. COGT's yearly revenue for 2021 was $0, representing a decrease of -100.00% compared to 2020.
What is Cogent Biosciences’s quarterly revenue?
Cogent Biosciences's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). COGT's quarterly revenue for Q4 2023 was $5.59M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Cogent Biosciences’s revenue growth rate?
Cogent Biosciences's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -100.00%.
What are Cogent Biosciences’s revenue streams?
Cogent Biosciences's revenue streams in c 19 are Preclinical Research And Clinical Development
What is Cogent Biosciences’s main source of revenue?
For the fiscal year ending Dec 19, the largest source of revenue of Cogent Biosciences was Preclinical Research And Clinical Development. This segment made a revenue of $25M, representing 100.00% of the company's total revenue.